Erratum

Br J Clin Pharmacol 2003; 56 (1); 46–56.

A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar (LY335979)

S. Callies, D. P de Alwis, A. Harris, P. Vasey, J. H. Beijnen, J. H. Schellens, M. Burgess & L. Aarons

P. 52. The publisher regrets that Table 3 was printed incorrectly. The correct Table is printed below.

Table 3 Paclitaxel pharmacokinetic parameters from the basic and covariate (categorical and continous) population pharmacokinetic models.

	Basic model	*Categorical relationship (final model)*	*Continuous relationship*
OBJF	8727.003	8703.350	8680.895
Parameters (value (SE%))			
CL changing with time⋆			
Slope (θ_2) (l h^{-2})	9.35 (7.32)	10.0 (7.92)	9.66 (6.95)
Min CL (θ_1) (l h^{-1})	7.64 (12.2)	8.48 (12.9)	8.59 (29.9)
t_{50} (θ_4) (h)	8.76 (16.4)	9.36 (28.2)	7.27 (102)
γ_1 (θ_3)	2.94 (23.5)	2.68 (30.2)	2.12 (95.3)
Effect of zosuquidar on paclitaxel CL			
Decrease with LY C_{max} >350 (μg l^{-1}) (%)	–	25.2 (12.4)	–
E_{max} (l h^{-1})	–	–	5.49 (43.5)
LY C_{max50} (μg l^{-1})	–	–	328 (15.4)
γ_2	–	–	9.18 (129)
V_1 (l)	7.93 (14.0)	7.95 (13.8)	8.38 (13.0)
V_2 (l)	198 (7.78)	196 (7.81)	194 (16.0)
Q_2 (l h^{-1})	11.1 (7.37)	10.8 (9.35)	11.2 (11.3)
Q_3 (l h^{-1})	6.57 (15.8)	6.76 (16.4)	6.35 (39.4)
V_3(l)	7.00 (15.4)	7.51 (18.9)	10.2 (164)
ω CL (%)	27.2 (33.2)	25.9 (29.7)	24.8 (34.3)
ω CL-Q_2 (%)	32.6 (23.4)	30.5 (23.2)	29.6 (24.7)
ω Q_2 (%)	44.5 (28.0)	43.7 (26.1)	43.5 (37.0)
ω CL-V_2 (%)	29.3 (30.7)	26.1 (38.4)	24.2 (39.5)
ω Q2-V_2 (%)	40.7 (29.9)	39.6 (29.2)	37.5 (35.1)
ω V_2 (%)	43.7 (26.6)	42.8 (26.0)	40.9 (31.4)
ω V_1 (%)	38.5 (58.6)	40.0 (52.4)	41.7 (58.6)
ω IOV CL (%)	20.9 (33.2)	15.2 (53.9)	16.1 (56.2)
ω IOV V_1 (%)	57.5 (39.6)	54.5 (42.8)	46.6 (47.9)
Residual variance (%)	22.7 (7.75)	22.9 (7.77)	22.5 (8.00)

⋆During the infusion ⋆postinfusion $TCL = \theta_1 + \frac{\theta_2 * INF * (time - INF)^{\theta_3}}{\theta_4^{\theta_3} + (time - INF)^{\theta_3}}$ with INF the length of the infusion and time the time from the start of the infusion.